AFTER WHAT HAS BEEN A GOOD MONTH FOR THE PHARMA SECTOR INVESTORS IN ALXN EAGERLY AWAIT THE FDA'S RULING ON BLAFOR SOLIRIS TO BE USED IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER, THEY DECISION IS DUE FRIDAY AND THE OPTIONS MARKET HAS BEEN QUITE ACTIVE WITH A PROJECTED 4% MOVE.
AVERAGE ANALYSTS PRICE TARGET $161
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 68
COMPANY PROFILE
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.
AVERAGE ANALYSTS PRICE TARGET $161
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 68
COMPANY PROFILE
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.